Patiromer
- Generic Name
- Patiromer
- Brand Names
- Veltassa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1260643-52-4
- Unique Ingredient Identifier
- 1FQ2RY5YHH
- Background
Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2...
- Indication
Patiromer is indicated for the treatment of hyperkalemia.
- Associated Conditions
- Hyperkalemia
- Associated Therapies
- -
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Vifor Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05766839
- Locations
- 🇺🇸
UF Health Pediatric Multispecialty Center, Jacksonville, Florida, United States
🇺🇸Miller School of Medicine, University of Miami, Miami, Florida, United States
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
Comparison of Potassium Binders in the ER
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 120
- Registration Number
- NCT04585542
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
RELieving Increasing oEdema Due to Heart Failure
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 4
- Registration Number
- NCT04142788
- Locations
- 🇬🇧
Basildon University Hospital, Basildon, United Kingdom
🇬🇧Glasgow Royal Infirmary, Glasgow, Strathclyde, United Kingdom
🇬🇧Victoria Hospital, Kirkcaldy, United Kingdom
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Vifor Pharma, Inc.
- Target Recruit Count
- 1195
- Registration Number
- NCT03888066
- Locations
- 🇺🇸
Investigator Site 11-088, Haddon Heights, New Jersey, United States
🇺🇸Investigator Site 11-148, New Brunswick, New Jersey, United States
🇺🇸Investigator Site 11-054, Linden, New Jersey, United States
Exploratory Study of ZG-801 for the Treatment of Hyperkalemia
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- Zeria Pharmaceutical
- Target Recruit Count
- 184
- Registration Number
- NCT03799926
- Locations
- 🇯🇵
Zeria Investigative Sites, Kanagawa, Japan
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Dominic Raj
- Target Recruit Count
- 27
- Registration Number
- NCT03326583
- Locations
- 🇺🇸
DaVita K Street, Washington, District of Columbia, United States
Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 8
- Registration Number
- NCT03229265
- Locations
- 🇺🇸
The Rogosin Institute, New York, New York, United States
Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.
- Conditions
- Interventions
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 3
- Registration Number
- NCT03183778
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Vifor Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03087058
- Locations
- 🇺🇸
Investigator Site 1101, Kansas City, Kansas, United States
🇧🇬Investigator Site 1401, Sofia, Bulgaria
🇵🇱Investigator Site 5404, Gdansk, Poland
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 295
- Registration Number
- NCT03071263
- Locations
- 🇧🇬
Investigator Site 1402, Sofia, Bulgaria
🇺🇸Investigator Site 1022, Chicago, Illinois, United States
🇺🇸Investigator Site 1023, Miami Lakes, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.